Citations

Clear

6274 citation(s) found for "To, Andrew".

Abstract 10726: Cardiac Resynchronization Therapy Response in Cardiac Sarcoidosis
Shabtaie, Samuel A. , Lee, Justin Z. , Cha, Yong‐Mei , Bois, John P. , Rosenbaum, Andrew , Siontis, Konstantinos C. , Mulpuru, Siva K. , Deshmukh, Abhishek , DeSimone, Christopher V. , Kapa, Suraj , AbouEzzeddine, Omar F.

Mayo Clinic

Circulation | March 19, 2022 | Volume: 144 | Issue: Suppl_1 | Pages: No page available

10.1161/circ.144.suppl_1.10726 Get It

Introduction: Cardiac Sarcoidosis (CS) is a non-ischemic cardiomyopathy (NICM) characterized by infiltration of non-caseating granulomas involving in the heart with highly variable clinical manifestations. Cardiac resynchronization therapy (CRT) has shown significant promise in NICM, though little is known about its effectiveness in patients with CS. Hypothesis: We sought to determine if CRT improved cardiac remodeling and reduced hospitalizations in patients with CS. Methods: We retrospectively reviewed all patients with a clinical or histological diagnosis of CS who underwent CRT implantation at a Mayo Clinic site from 2000-2021. Baseline characteristics, echocardiographic parameters, heart failure hospitalization, and major adverse cardiac events (MACE) were assessed. Results: Our cohort was comprised of 55 patients with 61.8% male and a mean age of 58.7 ± 10.9 years. At baseline, 38 (69.1%) patients had isolated CS, while 17 (30.9%) had evidence of CS with extra-cardiac sarcoidosis. The overwhelming majority underwent CRT-D implantation (n=52, 94.5%) with 67.3% of implanted devices upgrades from prior pacemaker or implantable cardioverter defibrillator. At 6 months post-implantation there was no significant different in ejection fraction (34.8 ± 10.9 % vs. 37.7 ± 14.2 %, p = 0.237), left ventricular end systolic diameter (49.1 ± 9.9 mm vs. 45.7 ± 9.9 mm, p = 0.077) or left ventricular end-diastolic diameter (58.5 ± 10.2 mm vs. 57.5 ± 8.1 mm, p = 0.574). Within the first 6 months post-implantation, 5 (9.1%) patients sustained a heart failure hospitalization. At a mean follow up of 4.1 ± 3.7 years, 14 (25.5%) patients experienced a heart failure hospitalization, 11 (20.0%) underwent cardiac transplantation, 1 (1.8%) underwent LVAD implantation and 7 (12.7%) patients died. Conclusions: Our findings suggest a poor response to CRT in patients with CS with no significant evidence of reverse remodeling within 6 months and a substantial proportion of patients progressing to advanced heart failure therapies.
Abstract 9741: A Novel Mutation Identified in a Large Multi-Generational Family With Long QT Syndrome Reveals Distinct, Disease-Specific Mutation Hot Spots within the CACNA1C- Encoded L-type Calcium Channel
Boczek, Nicole J. , Ye, Dan , Allen, Hugh D. , Ackerman, Michael J. , Landstrom, Andrew P. , Kim, Jeffrey J.

Mayo Clinic

Circulation | March 19, 2022 | Volume: 132 | Issue: suppl_3 | Pages: No page available

10.1161/circ.132.suppl_3.9741 Get It

Background: Mutations in the CACNA1C-encoded L-type calcium channel have been associated with Timothy Syndrome (TS) with severe QT prolongation, cardiac hypertrophy, syndactyly, facial dysmorphisms, developmental delay, and sudden death by impaired channel inactivation and increase peak current. Recently, a small number of patients with CACNA1C mutations with only long QT syndrome (LQTS) have been described. Objective: To explore whether CACNA1C mutations associated with TS were mechanistically and clinically distinct from CACNA1C-mediated LQTS. Methods/Results: Illumina HiSeq 2000 platform-based whole exome sequencing with variant alignment using HGSC Mercury analysis and Atlas2 revealed a novel variant CACNA1C-L762F that co-segregated with affected patients of a large, multi-generational family with LQTS and sudden death. The proband presented at 3 years of age with out-of-hospital cardiac arrest and demonstrated QTc of 530. The mutation localized to the DII/DIII intracellular linker domain of the channel in a highly conserved region in close proximity to the 6th DI transmembrane domain. Whole cell patch clamp of heterologously expressed CACNA1C-L762F in TSA201 cells demonstrated slower inactivation tau and increased late current indicating its gain-of-function cellular electrophysiological phenotype. Comprehensive review and topological mapping of all described CACNA1C mutations associated with TS or LQTS revealed disease-specific hotspots. TS-associated mutations localized to cytoplasmic aspects of transmembrane domains while LQTS-associated mutations localized to cytoplasmic N- and C-terminal domains and linker regions. Probands hosting TS mutations demonstrated markedly prolonged QTc values compared to LQTS (618 vs 486 ms, p<0.001) and were younger at presentation (2.7 vs 20.1 years, p<0.002). Supporting these associations, the L762F mutation localized closer to the CACNA1C transmembrane domain than any other LQTS mutation and are associated with a QTc and age of diagnosis reflective of TS-associated mutations. Conclusions: The CACNA1C-L762F mutation is associated with biochemical and clinical features which highlight a molecular and clinical distinction between TS- and LQTS-associated CACNA1C mutations.
Abstract 270: Decrease of BNP Concentrations in Blood Perfusing Extremities of Patients with Advanced Peripheral Arterial Disease
Kurklinsky, Andrew K., Heublein, Denise M., Stockland, Andrew H., McPhail, Ian R., Friese, J., Andrews, James C. , Oderich, Gustavo S. , Burnett, John C. , Bjarnason, Haraldur , Misra, Sanjay , Oderich, Gustavo S.

Mayo Clinic

Arteriosclerosis, Thrombosis, and Vascular Biology | March 19, 2022 | Volume: 32 | Issue: suppl_1 | Pages: No page available

10.1161/atvb.32.suppl_1.a270 Get It

Rationale: The role of cardiac natriuretic peptides (NPs) in peripheral arterial disease (PAD) or thromboangiitis obliterans (TA) is unknown. Recent studies in mice suggested that BNP may be produced outside the heart in the ischemic limbs contributing to peripheral angiogenesis. Objective: Determine if synthesis or consumption/degradation of NPs occur in the ischemic legs of patients with PAD or TA. Methods: 32 patients with critical limb ischemia (CLI) or claudication (PAD n=31; TA n=1; 20 males; mean age 72.9 years) underwent diagnostic angiography or revascularization. We determined differences of concentrations of BNP, NT-proBNP, and CNP in the blood of proximal veins and arteries of both legs. Concentrations differences were then compared between the more ischemic target and the contralateral self-control legs. Results: Values are means ± SD. P values <0.05 were considered significant. In the PAD group, in the target extremity, concentration step-ups of NT-proBNP (11±68; p=0.40) and CNP (0.45±6.22; p=0.71) were not significant from the arterial to venous blood. In the contralateral self-control legs, NT-proBNP and CNP concentrations drops were also not significant (-37±160, p=0.7; -0.89±4.09, p=0.23). Venous BNP concentrations were significantly lower than arterial both in the target (-66±153, p<0.001) and self-control legs (-59±107, p<0.001). BNP concentrations drops were greater in the CLI than claudication cases driving the overall significance. In the patient with TA, whose only identifiable PAD risk factor was smoking, arterial concentrations of NPs were generally low (NT-proBNP 81; BNP 46; CNP 8.2), but higher than venous concentrations (80; 41; 6.7). Conclusion: Significantly lower venous BNP concentrations suggest possible BNP consumption/degradation in the ischemic legs. Concentrations of NT-proBNP, that has a longer half-life than BNP, were more stable suggesting no significant local production or conversion to BNP. CNP concentrations were stable. Recognizing the angiogenic properties of NPs and lack of evidence of peripheral production, studies are warranted in humans with PAD to determine the potential angiogenic properties of exogenous NPs supplementation in what could be considered a local NPs deficiency state.
Allergic airway recall responses require IL-9 from resident memory CD4 + T cells
Ulrich, Benjamin J. , Kharwadkar, Rakshin , Chu, Michelle , Pajulas, Abigail , Muralidharan, Charanya , Koh, Byunghee , Fu, Yongyao , Gao, Hongyu , Hayes, Tristan , Zhou, Hongming , Goplen, Nick P., Nelson, Andrew S. , Turner, Matthew J. , Licona-Limón, Paula , Kaplan, Mark H. , Hayes, Tristan A , Zhou, Hong-Ming , Goplen, Nicholas P , Liu, Yunlong , Linnemann, Amelia K , Turner, Matthew J , Licona-Limón, Paula , Flavell, Richard A , Sun, Jie , Kaplan, Mark H , Flavell, Richard A. , Sun, Jie

Mayo Clinic

Science Immunology | March 18, 2022 | Volume: 7 | Issue: 69 | Pages: No page available

10.1126/sciimmunol.abg9296 | PMID 35302861 Get It

Asthma is a chronic inflammatory lung disease with intermittent flares predominately mediated through memory T cells. Yet, the identity of long-term memory cells that mediate allergic recall responses is not well defined. In this report, using a mouse model of chronic allergen exposure followed by an allergen-free rest period, we characterized a subpopulation of CD4 + T cells that secreted IL-9 as an obligate effector cytokine. IL-9–secreting cells had a resident memory T cell phenotype, and blocking IL-9 during a recall challenge or deleting IL-9 from T cells significantly diminished airway inflammation and airway hyperreactivity. T cells secreted IL-9 in an allergen recall–specific manner, and secretion was amplified by IL-33. Using scRNA-seq and scATAC-seq, we defined the cellular identity of a distinct population of T cells with a proallergic cytokine pattern. Thus, in a recall model of allergic airway inflammation, IL-9 secretion from a multicytokine-producing CD4 + T cell population was required for an allergen recall response.
Benefit of Continuous Glucose Monitoring in Reducing Hypoglycemia Is Sustained Through 12 Months of Use Among Older Adults with Type 1 Diabetes
Miller, Kellee M. , Kanapka, Lauren , Ahmann, Andrew , Ang, Lynn , Bhargava, Anuj , Bode, Bruce W. , Carlson, Anders L. , Chaytor, Naomi , Gannon, Gail, Goland, Robin, Kiblinger, Lisa, Kruger, Davida , Kudva, Yogish C. , O’Malley, Grenye , Philis‐Tsimikas, Athena , Salam, Maamoun , Thompson, Michael , Vendrame, Francesco , Verdejo, Alandra , Weinstock, Ruth S. , Young, Laura , Group, for the WISDM Study, Kanapka, Lauren G , Kudva, Yogish C. , Peters, Anne L , Philis-Tsimikas, Athena , Shah, Viral N , Weinstock, Ruth S , Rickels, Michael R. , Aleppo, Grazia , Hirsch, Irl B. , Levy, Carol J. , McGill, Janet B. , Peters, Anne L. , Philipson, Louis H. , Pop‐Busui, Rodica , Shah, Viral N. , Pratley, Richard E. , Group, for the WISDM Study

Mayo Clinic

Diabetes Technology & Therapeutics | March 16, 2022 | Volume: 24 | Issue: 6 | Pages: 424-434

10.1089/dia.2021.0503 | PMID 35294272 Get It

Objective: To evaluate glycemic outcomes in the Wireless Innovation for Seniors with Diabetes Mellitus (WISDM) randomized clinical trial (RCT) participants during an observational extension phase. Research Design and Methods: WISDM RCT was a 26-week RCT comparing continuous glucose monitoring (CGM) with blood glucose monitoring (BGM) in 203 adults aged ≥60 years with type 1 diabetes. Of the 198 participants who completed the RCT, 100 (98%) CGM group participants continued CGM (CGM-CGM cohort) and 94 (98%) BGM group participants initiated CGM (BGM-CGM cohort) for an additional 26 weeks. Results: CGM was used a median of >90% of the time at 52 weeks in both cohorts. In the CGM-CGM cohort, median time <70 mg/dL decreased from 5.0% at baseline to 2.6% at 26 weeks and remained stable with a median of 2.8% at 52 weeks ( P < 0.001 baseline to 52 weeks). Participants spent more time in range 70–180 mg/dL (TIR) (mean 56% vs. 64%; P < 0.001) and had lower hemoglobin A1c (HbA1c) (mean 7.6% [59 mmol/mol] vs. 7.4% [57 mmol/mol]; P = 0.01) from baseline to 52 weeks. In BGM-CGM, from 26 to 52 weeks median time <70 mg/dL decreased from 3.9% to 1.9% ( P < 0.001), TIR increased from 56% to 60% ( P = 0.006) and HbA1c decreased from 7.5% (58 mmol/mol) to 7.3% (57 mmol/mol) ( P = 0.025). In BGM-CGM, a severe hypoglycemic event was reported for nine participants while using BGM during the RCT and for two participants during the extension phase with CGM ( P = 0.02). Conclusions: CGM use reduced hypoglycemia without increasing hyperglycemia in older adults with type 1 diabetes. These data provide further evidence for fully integrating CGM into clinical practice. Clinicaltrials.gov (NCT03240432)
Carfilzomib 56 mg/m 2 twice-weekly in combination with dexamethasone and daratumumab (KdD) versus daratumumab in combination with bortezomib and dexamethasone (DVd): a matching-adjusted indirect treatment
Terpos, Evangelos , Spencer, Andrew , Goldschmidt, Hartmut , Dirnberger, Franziska, DeCosta, Lucy, Yusuf, Akeem , Kumar, Shaji , Terpos, Evangelos , Goldschmidt, Hartmut , Kumar, Shaji K , Weisel, Katja C , Nooka, Ajay K.

Mayo Clinic

Leukemia & Lymphoma | March 15, 2022 | Volume: 63 | Issue: 8 | Pages: 1887-1896

10.1080/10428194.2022.2047962 | PMID 35289710 Get It

Association of Indication for Hospitalization With Subsequent Amyloid Positron Emission Tomography and Magnetic Resonance Imaging Biomarkers
Šprung, Juraj , Laporta, Mariana L. , Petersen, Ronald C. , Mielke, Michelle M. , Jack, Clifford R. , Martin, David P. , Hanson, Andrew C. , Schroeder, Darrell R. , Schulte, Phillip J. , Przybelski, Scott A. , Morales, Diana J. Valencia , Vemuri, Prashanthi , Mielke, Michelle M , Valencia Morales, Diana J , Weingarten, Toby N , Vemuri, Prashanthi , Warner, David O , Jack, Clifford R , Sprung, J , Schroeder, Darrell , Knopman, David S. , Weingarten, Toby N. , Warner, David O.

Mayo Clinic

The Journals of Gerontology: Series A | March 12, 2022 | Volume: 78 | Issue: 2 | Pages: 304-313

10.1093/gerona/glac064 | PMID 35279026 Get It

AbstractBackgroundHospitalization in older age is associated with accelerated cognitive decline, typically preceded by neuropathologic changes. We assess the association between indication for hospitalization and brain neurodegeneration.MethodsIncluded were participants from the Mayo Clinic Study of Aging, a population-based longitudinal study, with ≥1 brain imaging available in those older than 60 years of age between 2004 and 2017. Primary analyses used linear mixed-effects models to assess association of hospitalization with changes in longitudinal trajectory of cortical thinning, amyloid accumulation, and white matter hyperintensities (WMH). Additional analyses were performed with imaging outcomes dichotomized (normal vs abnormal) using Cox proportional hazards regression.ResultsOf 2 480 participants, 1 966 had no hospitalization and 514 had ≥1 admission. Hospitalization was associated with accelerated cortical thinning (annual slope change −0.003 mm [95% confidence interval (CI) −0.005 to −0.001], p = .002), but not amyloid accumulation (0.003 [95% CI −0.001 to 0.006], p = .107), or WMH increase (0.011 cm3 [95% CI −0.001 to 0.023], p = .062). Interaction analyses assessing whether trajectory changes are dependent on admission type (medical vs surgical) found interactions for all outcomes. While surgical hospitalizations were not, medical hospitalizations were associated with accelerated cortical thinning (−0.004 mm [95% CI −0.008 to −0.001, p = .014); amyloid accumulation (0.010, [95% CI 0.002 to 0.017, p = .011), and WMH increase (0.035 cm3 [95% CI 0.012 to 0.058, p = .006). Hospitalization was not associated with developing abnormal cortical thinning (p = .407), amyloid accumulation (p = .596), or WMH/infarctions score (p = .565).ConclusionsMedical hospitalizations were associated with accelerated cortical thinning, amyloid accumulation, and WMH increases. These changes were modest and did not translate to increased risk for crossing the abnormality threshold.
Cancer and immune-mediated necrotizing myopathy: a longitudinal referral case-controlled outcomes evaluation
Shelly, Shahar , Beecher, Grayson , Milone, Margherita , Liewluck, Teerin , Ernste, Floranne C. , Triplett, James , Naddaf, Elie , Ζεκερίδου, Αναστασία , Pittock, Sean J. , Mills, John R. , Mandrekar, Jay , Pittock, S J , Liewluck, T , Naddaf, Elie , Shahar, Shelly , Beecher, Grayson , Triplett, James D , McKeon, Andrew , Dubey, Divyanshu , Klein, Christopher J.

Mayo Clinic

Rheumatology | March 11, 2022 | Volume: 62 | Issue: 1 | Pages: 281-289

10.1093/rheumatology/keac144 | PMID 35285492 Get It

AbstractObjectivesTo investigate immune-mediated necrotizing myopathy (IMNM) association with cancer and its clinical implications.MethodsIMNM cases were identified 1 January 2000 to 31 December 2020 matching sex and age controls (4:1).ResultsA total of 152 patients with IMNM were identified and among serologically tested, 60% (83/140) were HMGCR-IgG+, 14% (20/140) were SRP-IgG+ and 26% (37/140) were seronegative. Cancer rates were not significantly different between serological subgroups; 18.1% (15/83) HMGCR-IgG+, 25% (5/20) SRP-IgG+ and 30% (11/37) seronegative (P = 0.34). Cancer screening was performed within 12 months from IMNM diagnosis in 88% (134/152) (whole-body CT plus FDG-PET CT in 53, CT alone in 72 and FDG-PET alone in 9). FDG-PET/CT was positive in 73% (25/34) of cancers. Increasing age was the only risk associated with cancer (P = 0.02). The odds of developing cancer at ±3 or ±5 years from IMNM diagnosis was not higher than controls (OR = 0.49; CI: 0.325–0.76). Lifetime IMNM diagnosis of cancer was less compared with controls (OR = 0.5 CI: 0.33–0.78, P = 0.002). Most patients responded to treatment (137/147, P &lt; 0.001). Death and treatment response did not significantly differ between cancer [23% (8/34); 88% (29/33)] and non-cancer patients [19% (23/118); 92% (108/118)]. In total, 13% (20/152) of patients died during follow-up compared with 14% (41/290) of medicine and 16% (46/290) of neurology controls (P = 0.8). Seropositives had greater life expectancy than seronegatives (P = 0.01).ConclusionsGreater cancer risk is not observed in IMNM vs controls. Cancer screening in IMNM should be individualized based on age-personal and family history, including consideration of FDG-PET/CT. Immune-treatment response did not differ with cancer.
NCCN Guidelines® Insights: Head and Neck Cancers, Version 1.2022
Gillison, Maura L. , Maghami, Ellie, Spencer, Sharon, Pfister, David G. , Birkeland, Andrew C. , Busse, Paul M., Cmelak, Anthony J. , Eisele, David W. , Galloway, Thomas J. , Geiger, J.L. , Haddad, Robert I. , Hicks, Wesley L. , Hitchcock, Ying J. , Jimeno, Antonio , Leizman, Debra S., Mell, Loren K. , Mittal, Bharat B. , Pinto, Harlan A. , Rocco, James W. , Rodriguez, Cristina P. , Savvides, P. , Sher, David J. , Weber, Randal S. , Weinstein, Gregory S., Worden, Frank , Yom, Sue S. , Zhen, Weining, Burns, Jennifer L. , Darlow, Susan, Savvides, Panayiotis S, Haddad, Robert , Mittal, Bharat B , Yom, Sue S , Caudell, Jimmy J , Adkins, Douglas R. , Brizel, David M. , Colevas, Alexander Dimitrios , Schwartz, David A. , Shah, Jatin P. , John, Maie A. St. , Bruce, Justine Y.

Mayo Clinic

Journal of the National Comprehensive Cancer Network | March 11, 2022 | Volume: 20 | Issue: 3 | Pages: 224-234

10.6004/jnccn.2022.0016 | PMID 35276673 Get It

The NCCN Guidelines for Head and Neck Cancers address tumors arising in the oral cavity (including mucosal lip), pharynx, larynx, and paranasal sinuses. Occult primary cancer, salivary gland cancer, and mucosal melanoma (MM) are also addressed. The specific site of disease, stage, and pathologic findings guide treatment (eg, the appropriate surgical procedure, radiation targets, dose and fractionation of radiation, indications for systemic therapy). The NCCN Head and Neck Cancers Panel meets at least annually to review comments from reviewers within their institutions, examine relevant new data from publications and abstracts, and reevaluate and update their recommendations. These NCCN Guidelines Insights summarize the panel’s most recent recommendations regarding management of HPV-positive oropharynx cancer and ongoing research in this area.
Perioperative outcomes and survival after surgery for intramedullary spinal cord tumors: a single-institution series of 302 patients
Hersh, Andrew M., Patel, Jaimin, Pennington, Zach, Porras, Jose L., Goldsborough, Earl, Antar, Albert, Elsamadicy, Aladine A., Lubelski, Daniel, Wolinsky, Jean-Paul, Jallo, George, Gokaslan, Ziya L., Lo, Sheng-Fu Larry, Sciubba, Daniel M., Pennington, Zach , Antar, Albert , Pennington, Zach , Hersh, Andrew M., Patel, Jaimin, Porras, Jose L., Goldsborough, Earl F. , Elsamadicy, Aladine A., Lubelski, Daniel, Wolinsky, Jean-Paul, Jallo, George, Gokaslan, Ziya L., Lo, Sheng-Fu Larry, Sciubba, Daniel M.

Mayo Clinic

Journal of Neurosurgery: Spine | March 11, 2022 | Volume: 37 | Issue: 2 | Pages: 252-262

10.3171/2022.1.spine211235 | PMID 35213831 Get It

OBJECTIVE Intramedullary spinal cord tumors (IMSCTs) are rare neoplasms whose treatment is often technically challenging. Given the low volume seen at most centers, perioperative outcomes have been reported infrequently. Here, the authors present the largest single-institution series of IMSCTs, focusing on the clinical presentation, histological makeup, perioperative outcomes, and long-term survival of surgically treated patients. METHODS A cohort of patients operated on for primary IMSCTs at a comprehensive cancer center between June 2002 and May 2020 was retrospectively identified. Data on patient demographics, tumor histology, neuraxial location, baseline neurological status, functional deficits, and operative characteristics were collected. Perioperative outcomes of interest included length of stay, postoperative complications, readmission, reoperation, and discharge disposition. Data were compared across tumor histologies using the Kruskal-Wallis H test, chi-square test, and Fisher exact test. Pairwise comparisons were conducted using Tukey’s honest significant difference test, chi-square test, and Fisher exact test. Long-term survival was assessed across tumor categories and histological subtype using the log-rank test. RESULTS Three hundred two patients were included in the study (mean age 34.9 ± 19 years, 77% white, 57% male). The most common tumors were ependymomas (47%), astrocytomas (31%), and hemangioblastomas (11%). Ependymomas and hemangioblastomas disproportionately localized to the cervical cord (54% and 59%, respectively), whereas astrocytomas were distributed almost equally between the cervical cord (36%) and thoracic cord (38%). Clinical presentation, extent of functional dependence, and postoperative 30-day outcomes were largely independent of underlying tumor pathology, although tumors of the thoracic cord had worse American Spinal Injury Association (ASIA) grades than cervical tumors. Rates of gross-total resection were lower for astrocytomas than for ependymomas (54% vs 84%, p < 0.01) and hemangioblastomas (54% vs 100%, p < 0.01). Additionally, 30-day readmission rates were significantly higher for astrocytomas than ependymomas (14% vs 6%, p = 0.02). Overall survival was significantly affected by the underlying pathology, with astrocytomas having poorer associated prognoses (40% at 15 years) than ependymomas (81%) and hemangioblastomas (66%; p < 0.01) and patients with high-grade ependymomas and astrocytomas having poorer long-term survival than those with low-grade lesions (p < 0.01). CONCLUSIONS The neuraxial location of IMSCTs, extent of resection, and postoperative survival differed significantly across tumor pathologies. However, perioperative outcomes did not vary significantly across tumor cohorts, suggesting that operative details, rather than pathology, may have a stronger influence on the short-term clinical course, whereas pathology appears to have a stronger impact on long-term survival.